Literature DB >> 8831113

Interactions of selective serotonin reuptake inhibitors with subtypes of sigma receptors in rat brain.

N Narita1, K Hashimoto, S Tomitaka, Y Minabe.   

Abstract

The interactions of selective serotonin reuptake inhibitors and tricyclic antidepressants with subtypes of sigma receptors were investigated. The rank order of affinity (Ki values) from competition experiments of [3H](+)-pentazocine binding to sigma 1 sites was: fluvoxamine > sertraline > S(+)-fluoxetine > (+/-)-fluoxetine > citalopram > imipramine > paroxetine > desipramine > R(-)-fluoxetine > (+/-)-norfluoxetine. The Ki values of all drugs for sigma 2 sites were more than 1000 nM. Furthermore, all drugs were more potent at sigma 1 sites than at sigma 2 sites. These findings suggest that sigma receptors (sigma 1 site) may play, in some way, a role in the actions of selective serotonin reuptake inhibitors.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8831113     DOI: 10.1016/0014-2999(96)00254-3

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  65 in total

Review 1.  Sigma receptors: potential targets for a new class of antidepressant drug.

Authors:  James A Fishback; Matthew J Robson; Yan-Tong Xu; Rae R Matsumoto
Journal:  Pharmacol Ther       Date:  2010-05-11       Impact factor: 12.310

2.  The sigma-1 receptor chaperone as an inter-organelle signaling modulator.

Authors:  Tsung-Ping Su; Teruo Hayashi; Tangui Maurice; Shilpa Buch; Arnold E Ruoho
Journal:  Trends Pharmacol Sci       Date:  2010-10-01       Impact factor: 14.819

3.  Novel sigma (sigma) receptor agonists produce antidepressant-like effects in mice.

Authors:  Jiajia Wang; Aisha L Mack; Andrew Coop; Rae R Matsumoto
Journal:  Eur Neuropsychopharmacol       Date:  2007-03-21       Impact factor: 4.600

Review 4.  Pathological laughing and crying : epidemiology, pathophysiology and treatment.

Authors:  Hal S Wortzel; Timothy J Oster; C Alan Anderson; David B Arciniegas
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

5.  Norbenzomorphan Scaffold: Chemical Tool for Modulating Sigma Receptor-Subtype Selectivity.

Authors:  James J Sahn; Timothy R Hodges; Jessica Z Chan; Stephen F Martin
Journal:  ACS Med Chem Lett       Date:  2017-03-21       Impact factor: 4.345

Review 6.  Sigma-1 receptor ligands: potential in the treatment of neuropsychiatric disorders.

Authors:  Teruo Hayashi; Tsung-Ping Su
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

7.  The opposite effects of fluvoxamine and sertraline in the treatment of psychotic major depression: a case report.

Authors:  Akira Kishimoto; Ayako Todani; Junko Miura; Tetsuno Kitagaki; Kenji Hashimoto
Journal:  Ann Gen Psychiatry       Date:  2010-05-21       Impact factor: 3.455

8.  Fluvoxamine for aripiprazole-associated akathisia in patients with schizophrenia: a potential role of sigma-1 receptors.

Authors:  Tsutomu Furuse; Kenji Hashimoto
Journal:  Ann Gen Psychiatry       Date:  2010-03-06       Impact factor: 3.455

9.  Fluvoxamine for blonanserin-associated akathisia in patients with schizophrenia: report of five cases.

Authors:  Tsutomu Furuse; Kenji Hashimoto
Journal:  Ann Gen Psychiatry       Date:  2010-04-24       Impact factor: 3.455

10.  Pharmacology and therapeutic potential of sigma(1) receptor ligands.

Authors:  E J Cobos; J M Entrena; F R Nieto; C M Cendán; E Del Pozo
Journal:  Curr Neuropharmacol       Date:  2008-12       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.